← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCAHotBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Colorectal Cancer; Resectable Colorectal Carcinoma · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 71.7%임상시험 123상태 RECRUITING
ADCCHotBiologicGlaxoSmithKlinePreclinical

23-valent (Pneumococcal Vaccine, Polyvalent, Pneumococcal Vaccine, Polyvalent (23-valent))

HIV Infections; Hepatitis B · HIV Infections

#HIVInfections#ADC#Preclinical#인기#항체약물접합체+3
효능 ORR 94.99%임상시험 121상태 ACTIVE
ADCCHotBiologicGileadderuxtecan, sacituzumab gov…Phase 2

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

Urothelial Carcinoma; Muscle-invasive Bladder Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 44%임상시험 121상태 RECRUITING
ADCBHotBiologicSeagenPreclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#인기#항체약물접합체+3
효능 ORR 89.5%임상시험 118상태 ACTIVE
ADCAHotBiologicGenentech, Inc.Approved

Methylprednisolone (Methylprednisolone)

Rheumatoid Arthritis · Ann Arbor Stage IIB Hodgkin Lymphoma

#AnnArborStageIIBHodgkinLymphoma#ADC#Approved#인기#항체약물접합체+3
효능 ORR 88%임상시험 118상태 RECRUITING
AntibodyCHotAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#인기#항체+5
효능 ORR 37.4%임상시험 118상태 RECRUITING
ADCBHotBiologicAstellasvedotin plus pembrolizumab …Phase 3

EV (enfortumab vedotin, enfortumab vedotin (EV))

Urothelial Carcinoma (UC); Peripheral Nerve Disease · Carcinoma, Transitional Cell

#CarcinomaTransitionalCell#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 117상태 RECRUITING
AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5
효능 ORR 95%임상시험 115상태 RECRUITING
ADCCHotBiologicAdcendo ApSPhase 2

ADC (Antibody-drug conjugate, Antibody-drug conjugate (ADC))

Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma · Metastatic Soft Tissue Sarcoma

#MetastaticSoftTissueSarcoma#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 31.2%임상시험 114상태 RECRUITING
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 114상태 RECRUITING
AntibodyBHotRochePhase 3

R (Rituximab, Rituximab (R))

Primary Central Nervous System Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase3#인기#항체+4
효능 ORR 95%임상시험 114상태 ACTIVE
CGTCHotBiologicThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 113상태 DISCONTINUED
AntibodyBHotBiologicRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5
효능 ORR 91.2%임상시험 113상태 RECRUITING
ADCAHotBiologicUlrik LassenPhase 2

combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination))

Cancer; Tumors · Cancer

#Cancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 67.6%임상시험 112상태 RECRUITING
AntibodyAHotMerckvedotin plus pembrolizumab …Phase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#인기#항체+5
효능 ORR 93.5%임상시험 111상태 RECRUITING
ADCBHotBiologicFBD Biologics LimitedPhase 2

AUC 5 (Carboplatin, Carboplatin (AUC 5))

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 84%임상시험 110상태 RECRUITING
AntibodyBHotMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#인기#항체+3
효능 ORR 56.1%임상시험 110상태 ACTIVE
ADCBHotBiologicRochePhase 2

Liquid (Polatuzumab vedotin, Polatuzumab vedotin (Liquid))

Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 100%임상시험 109상태 ACTIVE
ADCCHotBiologicSCRI Development Innovations, L…Phase 3

everolimus (everolimus)

Intracranial Meningioma · Renal Cell Carcinoma

#RenalCellCarcinoma#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 78.4%임상시험 109상태 DISCONTINUED
ADCBHotBiologicNCIC Clinical Trials Groupvedotin, 120 mg intr…Phase 3

Epirubicin (Epirubicin)

Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 62.7%임상시험 108상태 RECRUITING

4 / 209 페이지

← 이전다음 →